APO-RIVASTIGMINE rivastigmine (as hydrogen tartrate) 3mg capsule bottle

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

rivastigmine hydrogen tartrate, Quantity: 4.8 mg

Pieejams no:

Arrotex Pharmaceuticals Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

rivastigmine hydrogen tartrate

Zāļu forma:

Capsule

Kompozīcija:

Excipient Ingredients: titanium dioxide; microcrystalline cellulose; Gelatin; maize starch; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Ievadīšanas:

Oral

Vienības iepakojumā:

56, 500, 100

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type

Produktu pārskats:

Visual Identification: Hard gelatine calsule with orange, opaque body and orange opaque cap. Imprinted "APO R3" in black ink, white to off white fill.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Autorizācija statuss:

Registered

Autorizācija datums:

2010-07-27